These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 20534650)

  • 1. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
    Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early relapses, onset of progression, and late outcome in multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Deluca GC; Muraro PA; Ebers GC
    JAMA Neurol; 2013 Feb; 70(2):214-22. PubMed ID: 23407713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How patients with multiple sclerosis acquire disability.
    Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
    Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a two-stage disability progression in multiple sclerosis.
    Leray E; Yaouanq J; Le Page E; Coustans M; Laplaud D; Oger J; Edan G
    Brain; 2010 Jul; 133(Pt 7):1900-13. PubMed ID: 20423930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
    Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand'Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T
    Brain; 2023 Nov; 146(11):4633-4644. PubMed ID: 37369086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.
    Kremenchutzky M; Cottrell D; Rice G; Hader W; Baskerville J; Koopman W; Ebers GC
    Brain; 1999 Oct; 122 ( Pt 10)():1941-50. PubMed ID: 10506095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
    Usta NC; Boz C; Terzi M
    Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
    Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
    Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of age with the clinical phenotype in multiple sclerosis.
    Scalfari A; Lederer C; Daumer M; Nicholas R; Ebers GC; Muraro PA
    Mult Scler; 2016 Nov; 22(13):1750-1758. PubMed ID: 26869531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and disability accumulation in multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Ebers GC; Muraro PA
    Neurology; 2011 Sep; 77(13):1246-52. PubMed ID: 21917763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
    Ouallet JC
    Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
    JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study.
    Zhang Y; Xu Y; Xu T; Yin H; Zhu Y; Peng B; Cui L
    Mult Scler Relat Disord; 2020 Nov; 46():102461. PubMed ID: 32862039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.